Bayer entered into an agreement with GW Pharmaceuticals to acquire exclusive US marketing rights to GW’s cannabis-based medicine, Sativex® for the pain-relief treatment for multiple sclerosis. Sativex® is in phase III clinical trials for the treatment of cancer pain and neuropathic pain. GW could receive US$41 M from Bayer if specific milestones are met.